65 results about "Mouse embryonic fibroblast" patented technology

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of mouse embryonic fibroblast feeder cells to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by defined components added to the culture environment that support rapid proliferation without differentiation. The medium contains an isotonic buffer, a blend of essential nutrients such as protein and lipids, and an effective growth factor or combination of factors that promote proliferation while inhibiting differentiation. Culturing human embryonic stem cells in fresh medium on an extracellular matrix according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.

This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy.

The invention provides a method for culturing human induced pluripotent stem cells (iPSCs) by using human bone marrow mesenchymal stem cells as a trophoblast. The method comprises the following steps of: obtaining the human iPSCs from child foreskin fibroblasts by using third to fifth generation human bone marrow mesenchymal stem cells obtained through subculture and culture after thawing from low-temperature freezing, performing amplification culture, and inoculating into trophoblast cells to obtain the human iPSCs. In the method, the human iPSCs are cultured by using the human bone marrow mesenchymal stem cells as the trophoblast cells instead of mouse embryonic fibroblasts in the conventional method, so that the pollution of heterologous cells in a culture system is reduced, that the culture system can make the human iPSCs amplified in vitro is proved, biological characteristics and multipotency of the human iPSCs are maintained for a long time, and the possibility of clinical application of the human iPSCs is provided.

The present invention relates to the field of traditional Chinese medicines, natural medicines and daily chemicals, particularly to a new Periplaneta Americana polypeptide capable of promoting tissue repair, and applications thereof, wherein the new polypeptide capable of promoting tissue repair is named Periplapeptide B, has a structure represented by a formula I, can promote the proliferation of mouse embryonic fibroblasts and the migration of human immortalized epidermal cells at a low concentration, has advantages of low toxic-side effect and good application prospect, and can be used for preparing drugs for treatment of trauma, scald and ulcer, or cosmetics for improving skin beauty, and daily chemicals. The formula I is H-Ala-Ala-Pro-Pro-Ser-Asn-Leu-Lys-Glu-Val-Pro-Ile-Ile-Ala-Tyr-OH.

The invention relates to a method for preparing an amniotic compound corneal limbus stem cell membrane, which comprises the following steps of: firstly, preparing a sterile amniotic membrane with epithelium removed, placing the epithelial surface of the amniotic membrane downwards on an end face of a sleeve made of a poly propylene material, and covering an embedded culture transwell on the amniotic membrane of the sleeve to obtain an amniotic-membrane-embedded culture mold; placing the culture mold in holes in a 6-hole plate on which a mouse embryonic fibroblast cell feeder layer is spread; and finally, preparing a corneal limbus stem cell suspension by using a digestion method, inoculating the suspension on the epithelial surface of the amniotic membrane, inoculating 2.0-3.0*10<5> corneal limbus stem cells for each culture mold, and culturing the corneal limbus stem cells for 10 days to obtain the amniotic compound corneal limbus stem cell membrane. Compared with the traditional amniotic membrane spreading method and the latex ring amniotic membrane fixing method, the amniotic compound corneal limbus stem cell membrane prepared with the method has flat amniotic membrane culturing surface and uniform corneal limbus stem cell stratified layer and especially has the advantage of convenience for clinic application and difficulty in rapture of the amniotic membrane.

The invention discloses a method for transfecting bovine somatic cells into inducted pluripotent stem cells (iPSCs) by adopting transcription factors, concretely comprising the following steps: 1) isolation and culture of bovine dermal fibroblasts; 2) cloning of bovine transcription factor genes maintaining pluripotency and construction of retroviral vectors of the transcription factor genes; 3) retrovirus packaging and preparation; and 4) infection of bovine dermal fibroblasts by retrovirus and acquisition of bovine inducted pluripotent stem cells. The invention first adopts the acellular human amniotic membranes as support to replace the mouse embryonic fibroblasts (MEFs) to maintain in vitro proliferation of the bovine iPSCs and keep the bovine iPSCs in undifferentiated pluripotent states for long time. The method which adopts gene inducing to generate the PSCs not only solves the technical problem that the PSCs of the animals such as cattle, sheep, pigs and other livestock are difficult to obtain but also avoids the problem of heterogeneous animal cell pollution caused by the feeder layer which applies the MEFs as the stem cells.

The invention discloses medical applications of four buxus alkaloids compounds in the preparation of antitumor medicines. Experiment results show that the four compounds KBA01, KBA02, KBA03 and KBR18, under the condition of concentration without toxicity to wild normal mouse embryonic fibroblast cells, can selectively kill mouse tumor cells with tumor specific mutant genes p53 and Ras; accordingly, the compounds are very strong in killing activity to human colon cancer cell strains with p53 mutants, but not strong in killing activity to human wild colon cancer cell strains with p53 mutants; and as shown in a GFP (Green Fluorescence Protein) reporter vector screening system of a gene promoter, the compounds KBA02 and KBA03 can activate a promoter of a cancer suppressor gene p16. The characteristics indicate that the compounds from the four buxus plant origins have application potentials for preparing personalized treatment medicines aiming at the tumor mutant genes p53 and Ras as well as the cancer suppressor gene p16.

The invention relates to the field of medicines and daily chemicals, in particular to a periplaneta americana new polypeptide for promoting tissue repair and application of the periplaneta americana new polypeptide, the structure of the periplaneta americana new polypeptide is shown as a formula I, and the periplaneta americana new polypeptide is named as a tissue repair factor PA1. The new polypeptide can promote proliferation of mouse embryo fibroblasts and migration of human immortalized epidermal cells even at a low concentration, has low toxic and side effects and has a good application prospect, so that the polypeptide can be used for preparing medicines for treating wounds, scalds and ulcers or cosmetics and daily chemical products for improving skin beauty.

The invention discloses a method for transfecting bovine somatic cells into inducted pluripotent stem cells (iPSCs) by adopting transcription factors, concretely comprising the following steps: 1) isolation and culture of bovine dermal fibroblasts; 2) cloning of bovine transcription factors maintaining pluripotent genes and construction of retroviral vectors of the transcription factors; 3) retrovirus packaging and preparation; and 4) infection of bovine dermal fibroblasts by retrovirus and acquisition of bovine inducted pluripotent stem cells. The invention first adopts the acellular human amniotic membranes as support to replace the mouse embryonic fibroblasts (MEFs) to maintain in vitro proliferation of the bovine iPSCs and keep the bovine iPSCs in undifferentiated pluripotent states for long time. The method which adopts gene inducing to generate the PSCs not only solves the technical problem that the PSCs of the animals such as cattle, sheep, pigs and other livestock are difficult to obtain but also avoids the problem of heterogeneous animal cell pollution caused by the feeder layer which applies the MEFs as the stem cells.

A method for isolating oogonial stem cells (OSCs) including forming an ovarian cell suspension from an ovary, forming ovaroids by culturing the ovarian cell suspension in a three-dimensional culture, and migrating the OSCs around the ovaroids by culturing the ovaroids on a mouse embryonic fibroblast (MEF)-coated plate.

The invention provides a cattle trophoderm stem cell system establishment method which comprises the following steps: inoculating hemiblastula of which zona pellucida is removed through pronase treatment into a feed layer in mouse embryonic fibroblast subjected to mitomycin treatment and Wnt-3A mouse subcutaneous connective tissue cells, adding 2i small-molecule inhibitor culture solution to perform continuous cell culture of cells, and establishing a cattle trophoderm stem cell system. The method can be used for obtaining and culturing cattle trophoderm stem cells under in-vitro conditions for a long time. The cattle trophoderm stem cell system establishment method can be applied to large animal transgenosis and somatic cell cloning and can be further used for cattle embryo implantation and placenta differentiation.

The invention discloses application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of an antitumor drug. The anti-HIV drug amprenavir identified by food and drug administration (FDA) is taken as a material; the killing effect of the amprenavir on a tumor cell is detected by adopting a microwave theory and techniques (MTT) method. An experiment proves that the amprenavir has a significant inhibiting effect on multiplication of a plurality of tumor cells, such as a breast cancer michigan cancer foundation (MCF-7) cell, a non-small cell lung cancer A549 cell, a mouse embryonic fibroblast glioblastoma multiforme L929 cell, a colon cancer HT29 cell, a brain glioma U87 cell and the like, so as to clarify new use of an old drug. Therefore, foundation is provided for development of a novel anti-tumor drug.

The invention relates to the technical field of biomedicine, in particular to a cell strain subjected to long-term passage after gamma ray irradiation of human skin fibroblasts (HFF-1) and a construction method of the cell strain. According to the invention, human skin fibroblasts (HFF-1) are used as induction objects, after the induction objects are subjected to a specific dose (10Gy) of gamma rays for irradiation and mouse embryo fibroblasts irradiation, the cell proliferation is slowed down, apoptosis is increased, the migration capacity is weakened, and the change of the characteristics ofthe cells is not changed along with the increase of cell passage number and can be inherited to the next generation along with the passage of the cells. The cell model is closer to clinical practiceof long-term non-healing of wounds after skin squamous cell carcinoma radiotherapy in practical application, and has important application prospects in the aspects of research of pathological mechanisms of non-healing of wounds after radiotherapy, research and development of new drugs and the like.

The invention provides a method for inhibiting PUMA function and improving iPS (induced Pluripotent Stem) cell construction effect. The method comprises the following steps of: (1) preparing fibroblast MEF (Mouse Embryonic Fibroblast) of a PUMA-/- (PUMA gene knocked out) mice or PUMA-/+ mice, and performing passage and frozen storage; (2) converting plasmid PMX-Oct 4, PMX-Sox2, PMX-c-Myc and PMX-KLF4 through DH5 alpha escherichia coli strain, and respectively highly and slightly extracting plasma; (3) packing retrovirus, tittering and performing frozen storage; (4) knocking out reprogramming of embryo fibroblasts MEF of the mice or PUMA-/+ mice through PUMA gene; and (5) knocking down the programming of human fibroblast of the PUMPA function. The method has the beneficial effects that the PUMA function is inhibited and the iPS cell construction effect is improved during programming somatic cell; the stability of iPS cell genome can be protected at the same time.

The invention discloses new application of a chromone compound KY12 in preparation of a targeted anti-tumor medicament. Experimental results show that the compound KY12 can selectively kill tumor cells with tumor specific mutant genes p53 and Ras under the concentration which is nontoxic for wild normal mouse embryo fibroblasts, namely the compound has application potential for preparing the personalized treatment medicament for the tumor specific mutant genes p53 and Ras.

The invention discloses a cimicifuga triterpenoid compound and application thereof in preparation of anti-tumor drugs. Shown by targeted screening results directed at tumor-specific mutation gene products, at the concentration of being non-toxic to wild-type normal mouse embryonic fibroblast, a compound KY40 can selectively kill tumor cells with tumor-specific mutation genes; and shown by a GFP (Green Fluorescent Protein) reporting vector screening system of a gene p16 promoter, the compound KY40 can act on the p16 promoter, and shown by the characteristics, the novel cimicifuga triterpenoid compound and pharmaceutical compositions taking the cimicifuga triterpenoid compound as an effective treatment amount have application potential in the preparation of individualized treatment drugs directed at tumor-specific mutation genes p53 and tumor suppressor genes p16.

The present invention discloses a method for improving induction efficiency of neural stem cells and promoting differentiation of neurons. A programmed induction of SMSINS cells is as follows: using LDN193189 (Selleck S2618, 0.25 [mu]M) and SB431542 (Selleck S1067, 1 [mu]M) on the 1st and 2nd days to treat mouse embryonic fibroblasts (MEFs); using CHIR99021 (Selleck S2924, 3 [mu]M) DAPT (Selleck S2215, 5 [mu]M) and VPA (Sigma P4543, 0.5 mM) on the 3rd and 4th day; using CHIR99021 (Selleck S2924, 3 [mu]M) and DAPT (Selleck S2215, 5 [mu]M) on the 5th and 6th days; adding Shh (Peprotech 315225, 100 ng/ml) and Purmorphamine (selleck S3042, 1 [mu]M) on the 7th and 8th days to improve neural differentiation; and removing all small molecule compounds on the 9th and 10th days and conducting changeto a NSC complete culture medium. At the time, SMSINS cells can be trypsinized into single cells and can be inoculated into 24-well plates without coating PDL/L in the NSC complete culture medium; and the SMSINS cells are subjected to in vitro neuronal differentiation. The method is simple and convenient to operate, can improve induction of the neural stem cells and promote the differentiation ofthe neurons, and is beneficial to popularization and application.

The invention relates to the technical field of medical application, and discloses a manganese-based nano-enzyme preparation (Mn-NPs) as a ferroptosis inhibitor and application of the manganese-based nano-enzyme preparation in liver injury. The manganese-based nano-enzyme preparation is applied to mouse embryo fibroblasts and living mice, and it is found that the manganese-based nano-enzyme preparation as a ferroptosis inhibitor can significantly inhibit cell ferroptosis induced by RSL3 and Erastin, has a long-term stable inhibition effect, and also has a relieving effect on acetaminophen (APAP)-induced mouse drug-induced liver injury.

The invention relates to a method for culturing human artificially induced pluripotent stem cells by using human amnion mesenchyme cells as a culture layer, which comprises the steps that: a human amnion mesenchyme cell culture medium is used, and exosomatic human amnion mesenchyme cells are cultured in a 15cm cell culture bottle for reaching 80 to 90 percent fusion; then, a human artificially induced pluripotent stem cell culture medium is added for use; and human artificially induced pluripotent stem cells put in the 15cm cell culture bottle are blown and beaten to be crushed into smaller stem cell masses, the stem cell masses are put into a human amnion mesenchyme cell culture bottle for culture, when human embryo stem cells grow to 4mm to 6mm, the stem cells are repeatedly blown and beaten to be crushed into smaller stem cell masses, and the stem cell masses are put into a new amnion mesenchyme cell culture bottle for continuous culture or are used for other purposes. By the method, cells with the same form as the human artificially induced pluripotent stem cells cultured on mouse embryonic fibroblast (MEF) are obtained, and in addition, higher safety is realized through beingcompared with the MEF culture.